A review of the data for Triumeq (dolutegravir/abacavir/lamivudine) that includes efficacy, tolerability, resistance, drug interactions and convenience.
IAS Sets
Summary Slide Sets
SINGLE – 144 Weeks
![SINGLE – 144 Weeks](/content/dam/global/hcpportal/master/images/homepage/products/triumeq/slideset5.jpg)
How does a dolutegravir-based regimen compare to Atripla® in treatment-naïve patients at 144 weeks?
SINGLE – 96 Weeks
How does a dolutegravir-based regimen compare to Atripla® in treatment-naïve patients at 96 weeks?
FLAMINGO – 96 Weeks
Efficacy and safety of a dolutegravir-based regimen versus a darunavir/r regimen in treatment-naïve subjects
TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare